Mer­ck un­veils RSV an­ti­body da­ta, in bid to com­pete with As­traZeneca and Sanofi

Mer­ck’s ex­per­i­men­tal an­ti­body for RSV re­duced in­fants’ risk of cer­tain low­er res­pi­ra­to­ry in­fec­tions by 60.4% com­pared to place­bo, meet­ing the tri­al’s pri­ma­ry end­point.

The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER